Selank vs Semax
A factual side-by-side from public databases — chemical identity, literature volume, and attributed independent-test coverage. Not a recommendation; we don't rank one above the other.
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro; a tuftsin analogue) is described in the provided literature as a neuroactive heptapeptide with reported anti-anxiety and nootropic-related effects in preclinical rat studies, and as a peptide discussed in the context of peptide therapeutics for nervous-system recovery. (PMIDs: 41490200, 31625062, 30255741, 28280289, 14552529)
Semax is a synthetic heptapeptide related to ACTH(4-7) with a C-terminal Pro-Gly-Pro tripeptide (ACTH(4-7)PGP). Research cited here includes studies in models of spinal cord injury, cerebral ischemia, and Alzheimer’s disease/amyloid-β aggregation, along with gene/protein expression profiling.
| Selank | Semax | |
|---|---|---|
| Family | Nootropic & regulatory peptides | Nootropic & regulatory peptides |
| Research goals | Cognitive & mood | Cognitive & mood |
| Amino acids | — | — |
| Molecular formula | C33H57N11O9 | C37H51N9O10S |
| Molecular weight | 751.9 g/mol | 813.9 g/mol |
| CAS number | 129954-34-3 | 80714-61-0 |
| Approx. half-life | — | — |
| Regulatory status | Research only | Research only |
| WADA status | — | — |
| Evidence maturity | — | — |
| Research references | 10 | 9 |
| Vendors independently tested | 0 | 0 |
| Best test score (Finnrick) | — | — |